Can a patient with atrial fibrillation and ischemic cardiomyopathy who is taking empagliflozin (Jardiance) and apixaban (Eliquis) safely undergo a colonoscopy, and how should these medications be managed around the procedure?

Colonoscopy Clearance for Patient on Eliquis and Jardiance

This patient can safely undergo colonoscopy with temporary interruption of Eliquis (apixaban) 48 hours before the procedure, while Jardiance (empagliflozin) should be continued without interruption.

Medication Management Strategy

Eliquis (Apixaban) Management

For diagnostic colonoscopy only (low-risk procedure):

• Omit the morning dose on the day of procedure 1
• Resume usual dosing after the procedure once hemostasis is confirmed

For colonoscopy with polypectomy (high-risk procedure):

• Stop Eliquis 48 hours before the procedure 1, 2
• The last dose should be taken at least 48 hours prior to the scheduled procedure time
• Resume Eliquis within 24-48 hours after the procedure, depending on bleeding risk and adequate hemostasis 1
• No bridging anticoagulation is needed 1, 2

The FDA label for Eliquis specifically states that the drug should be discontinued at least 48 hours prior to elective surgery or invasive procedures with moderate or high risk of bleeding, and that bridging anticoagulation during this period is not generally required 2.

Jardiance (Empagliflozin) Management

Continue Jardiance without interruption. There is no evidence requiring discontinuation of SGLT2 inhibitors like empagliflozin for colonoscopy. This medication does not affect bleeding risk or coagulation, and studies demonstrate its safety and efficacy in patients with atrial fibrillation and cardiomyopathy 3, 4.

Risk Stratification

Thrombotic Risk Assessment

This patient has low thrombotic risk based on current guidelines:

• Atrial fibrillation without valvular disease is classified as low-risk 1
• Ischemic cardiomyopathy alone does not elevate to high-risk category
• High-risk conditions requiring bridging include: prosthetic metal heart valves (especially mitral position), AF with mitral stenosis, or recent (<3 months) venous thromboembolism 1

Procedure Risk Assessment

Colonoscopy risk depends on planned intervention:

• Low-risk: Diagnostic colonoscopy with biopsies only 1
• High-risk: Polypectomy, endoscopic mucosal resection, stricture dilation 1

The BSG/ESGE guidelines clearly stratify endoscopic polypectomy as a high-risk procedure for bleeding 1. Even with warfarin interruption, post-polypectomy bleeding rates range from 0.8% to 14% depending on technique, with cold snaring showing significantly lower bleeding rates (0%) compared to hot snaring (14%) in anticoagulated patients 1.

Critical Clinical Considerations

Bleeding Risk Counseling

Advise the patient that even with appropriate Eliquis interruption, there remains an increased risk of post-procedure bleeding compared to non-anticoagulated patients 1. This risk persists for up to 2 weeks after polypectomy.

Polypectomy Technique

If polyps are found during colonoscopy, strongly recommend cold snare technique for polyps <1 cm rather than hot snare, as this reduces delayed bleeding risk from 14% to 0% in anticoagulated patients 1.

Renal Function Monitoring

While not directly affecting colonoscopy clearance, verify renal function (eGFR) before the procedure. If eGFR is 30-50 mL/min and the patient were on dabigatran (not applicable here with apixaban), a 72-hour interruption would be required 1. For apixaban, the 48-hour rule applies regardless of mild-moderate renal impairment.

Common Pitfalls to Avoid

1. Do NOT bridge with LMWH - The 2016 BSG/ESGE guidelines and subsequent evidence from the BRIDGE trial demonstrate that bridging in non-valvular AF increases bleeding risk without reducing thrombotic events 1

2. Do NOT continue Eliquis for high-risk procedures - While continuation may be considered for diagnostic procedures only, polypectomy requires interruption 5, 1

3. Do NOT stop Jardiance - There is no indication to interrupt SGLT2 inhibitors for endoscopic procedures

4. Do NOT delay resumption beyond 48 hours - Prolonged interruption increases stroke risk in AF patients without corresponding benefit 2

Post-Procedure Management

• Resume Eliquis at the usual dose (typically 5 mg twice daily, or 2.5 mg twice daily if dose-reduced) within 24-48 hours after adequate hemostasis is established 1, 2
• Continue Jardiance throughout the peri-procedural period
• Monitor for signs of delayed bleeding for 14 days post-polypectomy
• Ensure patient understands warning signs: black/tarry stools, bright red rectal bleeding, dizziness, or weakness 2